Earnings Call: Q2 2018

Aug 14, 2018

Ladies, ladies and gentlemen, thank you for standing by. I am Sabrina, your call operator. Welcome, and thank you for joining the Finwise AG Healthcare 2018 Results Conference Call. In the beginning of today's call, all participants will be in a listen only mode. The presentation will be followed by a question and answer session. If any participants has been speaking to here in the conference call, please press the star key followed by 0, followed by 0, followed by 0, followed by a solar system. I'm now I now hand over to your host for today's call. Please go to. Please go ahead, sir. Thank you very much, Lavina. Good morning, and welcome to our analyst and investor call on the occasion of the publication of our half year results for the period January to June 2018. All corresponding materials, including the presentation, have been published on our 5 this morning. A replay of the call will be available later today. Today's call will be helped by our CEO, Doctor. Heinz Thunbelkham, and our CFO, Rudolf Kingon. After their presentations, we are open for your questions. With this, I hand over to our CEO, Doctor Johnson, you may begin. Thank you, Tobias. Good morning, everyone. Welcome, and thank you for joining our earnings call on the results for the first half of twenty eighteen. In today's call, I want to give you an update on our latest performance and the strategic initiative Our CFO, Walas Kina, will guide you through the financials in detail. After we close our presentation, with our updated outlook. We will give you, opportunity, for questions. Let's ask it off for the highlights on slide 3. After the dynamic first quarter, we accelerated our growth course between April June. Given the challenges in the market, we think that is excellent news. We we call organic sales growth of 9 percent to €1,600,000,000. Our EBITDA amounts to 3 100 and 70,000,000 with an EBITDA margin of 20.1%. We remained very profitable. Net income increased to €142,000,000 with an earnings per share rising to 10¢. Against the background of our strong performance in the first half, we waived our sales guidance for 2018. We now expect organic sales to exceed 7%. The stock market appreciates our performance as well as our ambition. Our market cap reached €10,000,000,000. Similarly has continued to be a frontrunner with respect to growth on slide 4 Industry. During the first half of this year, we increased organic sales by an excellent 9 percent to €1,600,000,000. It is not based in the 2nd quarter and greenfield are even 10.6%. Taking into consideration for full effect and increased headwinds from unfavorable change rate. Our sales growth amounts to solid 4%. Let me give you more detail on the regional development on slide 5. Latin America was our strongest region with a sales growth of more than 16%. In the second quarter, the region delivered an even stronger result and increased its top line by even more than 20%. Asia Pacific ranks, 2nd, with the sales growth of more than 12%. In EMEA, we grew revenues by 7% and in North America, we realized solid growth of 5%. In Emerging Markets, we also operated extremely well with a double digit sales growth of about 13%. Overall, we generated 43 percent of our total group served in these dynamic markets. Charge 6 illustrates the individual effects and group sales team details. On an organic basis, it grew by 137,000,000. The acquisitions for Closos and Cabello contributed €32,000,000, currency effects in the volume of €109,000,000 impacted our top line by minus 7.2 percent. Let us come to the segment now. Please go into child coverage. Physical care increased 3.4 percent to €660,000,000. On an organic basis, this segment rule is top line by more than 10%. Dynamics were particularly good in all of our molecules and cosmetic ingredients. Each business delivered double digits greatly. Performance performance is particularly remarkable against the background of the raw material shortages. The availability of Citroen, which is a key component for fragrance compositions has further declined during the second quarter. Due to ongoing manufacturing difficulties amongst the data market suppliers. But thanks to our comprehensive backlog integration and our direct access to fragrance ingredients via Pilsa, we have compensated this charge. In other words, we had no disruption in our customer supply chain whatsoever. Our deliveries have been very reliable as always. Our strategic investment in Toyota clearly face off. Let's turn to slide 84, an overview of our Toyota business. Despite negative effect, it executes the segment delivered sales growth of 9% to around €605,000,000. Our UK based, average business cover continued €27,500,000. We also strongly grew on an organic basis with a plus of about 11%. All application areas in imaging expanded their business significantly. They are particularly benefited from new business and high price levels with vanilla applications. In addition, we have strong demand for sweet, savory, and beverages. For details on nutrition, please turn to Chart 9. The segment posted sales of about € 311,000,000 with a very good dynamic in pet food and food. A slight decline compared to the prior year is due to a temporary, slower order intake of 1 of Provin's main customers. Without this temporary customer effect, Nutrition grew 5 by very good 7.6%. We have already seen a stronger order intake in the second quarter and expect COVID's customers to be fully back in the second half. Let me now hand over to Olaf for more details on our financial. Olaf? Thank you, Antonio. Ladies and gentlemen, also welcome for my side. And as usual, I'll walk you through our financial performance in some more detail. Let me also give you some more context around our lives, which we think are strong. Given the environment we are navigating through right now. In fact, they might very successfully manage the challenges from exchange rates as well as from the market wide shortage of raw materials. We continue to face stiff foreign exchange headwinds in the 2nd quarter They were primarily a result of depreciation to you against the US dollar and led to a negative effect from foreign exchange rates of minus 6.5% since Q2, following minus 7.9% in Q1. Although the overall effects have slightly improved, we do expect this negative FX trend to continue in the second half of the year, but with less magnitudes. On a full year basis, we now foresee a headwind of 4% to 5%. On top of the currency headwind, The raw material situation remained tense due to the shortage in certain raw materials and a su surprise disruption by some of the biggest suppliers raw material costs continue to rise, especially for our Centene Care segment, but for different reasons, also in the flavor and nutrition segment. While we were able to counterbalance parts, we could, however, not compensate for it entirely. Given the current imbalance of supply and demand as well as the uncertainty in the supply chain, we remain somehow cautious. For the second half, we expect price levels to remain high and clearly above prior year. Your prices were already up by about 4%. For the full year 2018, we anticipate an increase in raw material prices between 4 5% more to the higher end. These challenges might have no further stop ups from making software, strategic investments, into growth initiatives. The underlying drivers of our business are fully intact. Our ongoing investments in R&D and in capacity expansion across the consequent implementation of our growth strategy. Although these steps cost and will temporarily impact profitability this year, they will pay off in the mid to long term. We are setting the basis for our future profitable growth by focusing on organic growth opportunities. Following this opening remarks, let us turn to the earnings development on Chart 11th. Group EBITDA came in at 317,100,000 after €322,900,000 in the compare period 2017. EBITDA growth was impacted by mainly 3 factors, higher raw material costs, unfavorable exchange rates, and our investments in strategic growth initiatives. Despite these effects, SIMRise continued to operate highly profitable. Our good EBITDA margin remained at a good level of 20.1% for the 1st 6 months and 20.2% for q 2. Coming to our segments, Centene Care was impacted the most other transformatory situation. However, despite the significantly higher raw material costs, segment EBITDA came in at 1,000,000 and was hand almost on prior year level. Accordingly, EBITDA margin amounted to a solid 19.4%. The segment's profitability speaks a clear language and once more and very directly illustrate the benefits of our strong raw material access. Please also note that the prior year EBITDA included a 1 off gain of €4,700,000 on the purchase price adjustment following the sale of the Panorama industrial activities. The flavor segment increased EBITDA by 3.2% to 1,000,000. EBITDA margin was at 21% and therefore, on an excellent level, taking the temporary diluting impact of the Cobalt acquisition into consideration. Nutrition saw temporary earnings decline during the first half. As Francine outlined, the reason behind it were lower trade contributions from Probi. In addition, the segment recorded ramp up costs for the new Diana side in the US and the magnitude of €2,000,000. EBITDA came in at €62,200,000 and profitability for the solid level is an EBITDA margin of 20%. Please turn now to Slide 12 for our bottom line. Despite higher manufacturing costs, Gross profit slightly increased to 1,000,000. Our gross margin on the other hand was down 1.4 basis points reflecting higher raw material costs. Depreciation increased by 2.1% and reflects our investment in various business areas. Amortization on the other side decreased by about 3% as an amortization period of an acquisition of the flavor, 2nd 2 1008, came to an end. Next financial result improved by €3,000,000 to minus €19,900,000, primarily due to the lower interest expenses related to our convertible bond. Net income grew to 100 and €42,300,000 and earnings per share rose to 1.10 Our tax rate remained fairly stable at 28% compared to 12 27.9% in the prior year period. It is also below our long term rate expectations of below 30% tax rate. Let us move now to our cash flow analysis on Slide 13. Operating cash flow amounted to a 151,200,000 And we saw a continuing increase in working capital. And in that context, drive us with strong business activities, higher raw material costs, both volume and price driven as well as strategic inventories, which we accumulated. Cash flow from investment activities was up €23,000,000 due to 2 factors. Reason M and A activity and the acquisition of, Chicago, which we closed at the beginning of the year. And second, growth and expansion projects in the US and China, the TransUnion will present in a minute. Financing cash flow decreased to minus 1,000,000 It has to be taken into account, however, that the prior year figure included a onetime effect related to the convertible bond issuance. Now to slide 14, present our balance sheet. Total assets increased by 3.7%. Receivables were up corresponding to top line growth and recent M and A activities. Outlined earlier, we saw an increase in inventory due to strong business dynamics as well as higher raw material prices. Current liabilities also increased primarily as a consequence of an increase in short term borrowings. Net debt, excluding pensions amounted to 2.4 times EBITDA or 1,500,000,000, including pension provisions, the ratio of net debt to EBITDA ratio, amounted to 3.3, which is slightly above our targeted range. Our increasingly strong focus on operating cash flow We'll have to bring this ratio down on a full year basis from expected 2.6to2.9 times EBITDA. There's an equity ratio of 37 percent. Sunrise continued to operate on a very solid capital base. All in all, we see ourselves financially in very well positioned to further drive forward our business in gross remission. With that, I would now like him for that to answer. Thank you. Thank you, Dola. I also want to take the opportunity to provide you with an update on our latest strategic investment and our expectations for the month ahead. And explained during our earnings call in March our CapEx will be at the higher end of this year, which means it will be at around 60% of sales. We experienced positive dynamics in all our regions and see strong opportunities for growth. It is, therefore, absolutely, consequence to leverage those opportunities. The basis for continuing our profitable growth course. Some of our current projects are presented on chart 16. In Shanghai, we now work in a new development center for Centrelent Care. In this modern facility, we developed fragrances in close cooperation with multinational and local clients for the Chinese market. In Spain, we have just extended our manufacturing capacity for pet food applications. In addition to the recent expansion in France, we now have another strong site for deliveries into various European markets. What are our trends going forward? In this month, we're going to open a new production for a facility for cosmetic ingredients in Charleston, South Carolina. That is where we also ramp up our mental capacities until early 2019. In October, we will start our new trade line for, facility for flavors in New Jersey, and we will open our new food ingredient site in Georgia. Beginning of q2 2019, our new fragrance encapsulation center and our team will become operational. Also, next year in Q4, our new facility for fragrances and flavors in China will take up operations. We invest more than €80,000,000 construction has already done. The various growth initiatives we undertake across different regions of the world underline of confidence. The long term growth drivers of our business as listed on child 17 are fully intact. In addition, similarly is very well positioned in the marketplace. We have a strong presence in developed and emerging markets, a broader customer base of the global, regional, and local customers and a diversified product portfolio, which we constantly expand. Equally as important, our backward integration, the results of the first half of this year speak a clear language. We have been able to manage the shortages in the market as we cover more than 60% of the raw materials, which we use through our network integration. Please turn to Chart 18. Following our strong performance during the 1st 6 months of 2018, we are positive for the second half. We have therefore waived our sales guidance. We now aim at organic sales growth of about 7% in 2018. We are confident that we have everything it takes to further expand customer relationships and we drive our top line. Our ambition to be among amongst the most profitable players in our industry is also unchanged. We therefore confirm our margin targets despite the pressure on raw material prices. We aim at an EBITDA margin of about 20 percent for the current year. Accordingly, our midterm targets for 2020 remain fully in place, we want to deliver an annual growth rate of 5 to 7% and we aim for EBITDA margin in the corridor of 19 to 20 percent. We would now like to open the call for your questions to be us. Please go ahead. Many thanks. I'm sharing with many things all up. Turning to Q And A, we are now happy to take your questions. We kindly ask you to put only two questions. If you cannot take all your questions during the conference, We will answer the remaining questions later today. Star followed by 1 on that touch tone telephone. If you wish to remove yourself from the question If you are using speaker replacement today, please leave your hands up before making your selection. And there's a question, my One moment for the first question please. The first question is from Patrick Lambert of Raymond James. Please go ahead. And then congratulations from your a 10.6% growth in q2. Just regarding that 10.6%, you know, could you break it between volume and prices, by segments, in Pakistan, the Centimeters Care, which was also very strong, the impact of of raising prices, how how much you you could price on to to customers? That's the question Number 1, and and and related to what it's the 20% growth in LatAm in q 2, how much is actually here? Pricing versus FX type of of growth. Thank you. Thank you, Patrick. I think Thank you. Hi. Take that. So on the volume price question that you're at, you saw in the half year of age is about, 1 quarter price and, 3 quarter volume. If you break that down a little bit further into the three segments, the picture for flavors is pretty much now moving to 1 quarter price and, 3 quarter volume. Nutrition is a fiftyfifty. So we see a lot of, price there at the moment, which is necessary to compensate also for raw material price increases in nutrition. And then CentranCare, very specific situations still, so on a half year, basis. There's some price now which came in in the second quarter, more to come in the second half of this year. But still, the majority of the gross is volume driven in Central Care. We are working on price increases with customers. We are done, substantial round is, the majority of the the customers, but it's definitely also necessary that we will look on further pricing costs. So and then on your question regarding LatAm, the gross is partly impacted by foreign exchange related to the US dollar euro development. So This is a good, very good growth momentum that we experienced at the moment in Japan and the good recovery, compared to last year. Especially also for Santander Care. The next question is from incorrect Heckman of Bernstein. Please go ahead. Hi. Good morning, everyone. I've got two questions. 1 on raw materials, and the other one coming back to prices. The first one, what inflation do you include in your budget for raw material costs in 2019 if you can give us an outlook there? And the second one, more clarification, the 45% of that you mentioned in the prepared remarks for cost inflation this year, Is that including or excluding the supply disruption? If I can take one more question to be then, do you expect to get any compensation for that supply interaction, either from the suppliers themselves or from insurance? So on the surprise situation, the guidance you gave, the 4 to 5 is more to the upper end of the range. It's everything. So you're not distinguishing between the trial and, the big picture situation, especially in Centen Care. Maybe also to add to that, we saw a further increase in 1 of 2 price development in infant care in the 2nd quarter. It was slightly less in in flavors, but still for the group perspective, at the higher end of 4 to 5. This is also a continuing, especially for Centimeters Care when we look into 2019. Hopefully, it will ease a little bit, but it's now very clear that, the driver is not only the situation. It's the the big picture, which we see in the world at the moment, pretty much also driven by China and some incidents in in India, which you're really aware of. So, we remain cautious. And as I said, we will have to work further on prices with customers to fully compensate the situation. So I hope that, that gives you a little bit of interest as you are. Sure. Thanks. And, anything on potential compensation for the current sector of supply disruption. The majority of the compensation has to come through, price, these customers. That is where we need to work and what we are actually doing. Our situation is slightly different than with some other competitors. That's why we do not break out as we, continue to say, we have, the materials we need, the impact we see is more on higher cost impact due to transportation, getting the materials there where we need it. But, the good news is our backward integration clearly pays off we have, fulfilled all customer orders. So that is a clear distinction between us and some others. So we have the material But as all I said, we are infected, but, getting compensation from anyone, that would be somewhat difficult. Okay. Great. Thank you both. The next question is from Heidi Vesterinen Alexandra. So, first, the question on growth. So, I think earlier this year, we had the impression that the step up in growth would be more 2019 story as the CapEx turns into volume. And now you're raising guidance today. So do you think the step up this year is driven by the 10th raw material situation where you had a clear advantage and maybe you gained share? And is the CapEx story for next year still intact, or are you seeing that some of the CapEx benefits that you were expecting are coming to earlier than expected. So maybe some of the expected growth from 2019 is just appearing earlier. So could you clarify that, please? And then secondly, on margins, could you talk a bit more about the self margin and flavors? You mentioned it was Cobalt related. Is it purely that? It was a bit surprising because everyone else has reported flavor margins up this season. And if I can sneak in a related question here, do you have an outlook our group margins into the second half. I think all of you have talked about progressive improvements, taking into account what you've said about raw material costs at are you still confident that margins could be a bit better as we go into the 2nd half? Thank you. Let me Thanks, Heidi. Let me first take the first question 1 after you just pick up the, yeah, Marvin part. On the CapEx, first, starting with the point, at least I hope it becomes obvious. Our CapEx, expansion project come in in time and are being completed in time. And, the good news the second good news is, obviously, they start to delivering some of the growth momentum which we were looking for. Having said that, the other positive news, our cosmetic ingredient plan to let me know that is already in operation. So also completed in time, and we're ramping it up as we're speaking. So But to the point, do we see, the CapEx project already contributing to the growth this year? Yes, but will they contribute also to growth next year? Yes. The good news for this is obviously our long term strategy plan pays off and Heidi, we have not taken back anything on our long term, ambitious, growth targets so that we we are still very confident in our business model. The only differentiator is, for this year as some of the momentum picked up very early. We even increased the guidance for this year. I think these are all positive news. Unless we wanna go through the margin, Yeah. So let me let me take up the flavor margin as I said. Cobre is definitely impacting the the margin situation, which is now with us for a year. That comes with a subcritical margin. We knew that, and we, of course, working on, level margin also for Cuber. So that will take some time that you said before, but, it's definitely and the control. The second element is that we tend to forget is that the vanilla price situation, was quite intensive. This is going into the last situation where I've done a tremendous job in flavors to manage through this dramatic price increase in in the middle. This is, I would say, the second small explanation why we see a little bit weaker margin environment and and flavor but giving the extremely strong growth profile, I think this is definitely compensated through the absolute EBITDA development and flavors. When it comes to the margin situation, the second half, I think we remain cautiously optimistic that we will further improve this. I would like to hand to the first quarter situation that we have the prior year effect in Pinnova was also one timer last year. And, we also still see the the COVID impact which is not only top line. It's also the EBITDA impact. And we should see the, the positive impact from the price negotiations which we had on the Centric Care side coming through in the second half, more prominent. So all this gives us some optimism with the challenge that the raw material price situation will be probably longer result than we expected. As I said, it's not only to trial, it's the overall environment, which is, the church. Okay. Yep. But, hi, JC. We'll even answer to your third question to the ball of strength. I appreciate that. Thank you. The next question is Yes, sir. Good morning. Good morning, gentlemen. I I will try you too as well. Firstly, on Vanilla is a if, if if you might have a better crystal than than than we have, I mean, obviously, the the next crop is coming up and eventually there will be there will be some price decreases for vanilla. Could you could could you just share your talks? How how do you think that will play out for you in in terms of of an eventual burden on you on your organic growth rates and and and and and on margin. And and secondly, just just very quickly on on CITROL. I I understand perfectly that, that you were able to buffer, most of the pressure via Pinnova, The question still remains with BSF producing again, do you expect a relief in terms of of margin in, from, from from the situation, from Q3, or is it still too early? Thank you. Okay. I pick up, first, the question of Manila. Thomas, it's, too early. There is no clear guidance if the price will go up will be on high level as it's currently or will go down. As The harvest team has, begun to your question. We have been talking with our people in Maharashtra, and they have started to buy some vanilla, but, just just started, and it's by far too early. At the moment, in that market, everyone is cautious in waiting what's going to see. So I hope that you will understand that we are also cautious as we don't know it better, and we will tell you otherwise So that is fresh information, I would say, from, from last week, talking with our people in Madagascar, on the other side, Yes. Yes. It's slowly coming back on track. They are not fully there yet, and they're they're distributing their secure not only to the fragrance industry, as you know, but also serving the, the vitamin industry and must not forget 2 other suppliers, have, still for us still under force majeure. And, so that we this month, material short in supply. So we expect there will be constraints in raw material supply in Q3 and Q4 going onward. But if that is said for us, this is on the one side challenge on the other side that opens opportunities. I hope that answers the question from this. This is very helpful. Thank you very much indeed. Of Fort Worth Research. Please go ahead. Yeah. Hi, gentlemen. Thanks for taking my questions. I've got one regarding your currently situation. You were looking at the last slide of your presentation. Could you maybe give us more detail in terms of the volume of the effects of it? You stated the 109,000,000 Is it rather, let's say, 60% U. S. Dollar related or rather 80% and maybe even the 2nd and third largest, currently, impact positions? And, in terms of your raised guidance of the above 7%, could you also provide an upper end maybe And, may maybe thirdly, I'll, create some color in terms of your your raw material price as well we discussed. And whether you've seen some other raw materials, and besides the villa, we would, have to watch out for or you're concerned about, or maybe there's some tailor developments coming up and maybe the impact on your gross margin as this is further declining, but you're at a gain mileage needs to be under control, February. All of, I would say, you take the currency part. Right? Have you been trying to view it? Yeah. So that's, of course, a very big part coming from the US dollar in absolute terms, but also keep in mind that the Latin currencies, are not helping at the moment right, for the contrary. So it's very much also preserved. It's Argentina. Argentina. It's Mexico. And then you have many currencies were also the euro strengthened at the end of the day. So it's pretty broad. The majority, clearly, coming from US dollar because it's about 1 third of our environment, top line wise. So that that's the the picture. Okay. It will be a little bit in the second half. Over the year, we expect 4 to 5% or headwind for the golf course. Patrick, may I I can't do the question on the gloves. Well, please bear in mind, our long term guidance 5 to 7 percent organic growth is already more ambitious than anyone else's. So and we're increasing it today for this year of more than 7% shows you we have a very strong confidence in our growth model, and it clearly shows our, initiatives, backward integration and also kinova, including, going in in that direction, clearly pays off today, it's too early to give you a clear picture on on what the year end will be, but I think for today, more than 7% I think that shows we are the growth value and we have a working business model. That leaves us with a question on raw materials about 75% of our raw materials are natural based, and I would say, in general, with the trend going towards more natural material and usage, the demand for, the natural materials will continue to be strong. And overall, I would say there is not something from the important materials where we will see a relief on the on the price at the sector. About 1 quarter of our materials is mineral oil based, and I would say, the development of the oil price. So it's obvious to you anyway so you can look this up on a day to day basis, but that gives you a picture on the raw material situation at the moment. I hope that answers your question, Patrick. So I think there was one more on the Vonage site. So I think given the environment, we manage our readiness, you know, if you have to increase prices, quite substantially, In fact, it has a diluting effect on the gross margin side. And as you rightly said, the EBITDA margin situation in these circumstances is very much under control, and I'm pretty proud of of our flavor period dates in this environment. And they were definitely able to pass through this price situation very well. So, all in all that definitely more than under control. Alright. Thank you very much. Welcome. The next question is from Daniel Vista of MainFirst Bank. Please go ahead. Yes. Thank you very much for taking my two questions. The first one on organic growth and Centennial Care coming back again. I mean, we will have said that it is mostly volume driven and that would mean we have seen a massive sequential acceleration compared to the previous quarter, Sam, can you put a bit more, color on this? Where this has come from and what are the Yeah. Are there any other pre shifting or why it is so strong now in Q2? And then second question, on on ramp up costs, you were highlighting that that you had 2,000,000 in in nutrition from from one side. Can you maybe give a bit more details on how it is for the whole group, how much rent, of course, you have in Q2 or in the first half. And, with more color on the phasing, what we can expect here. Thank you very much. Okay. Yeah. David. Our first organ growth in Centant Care, I I kept, saying we believe that, you know, I wasn't right acquisition. So a lot of the growth momentum came from the products from Pinova. Again, it's, an environment which gives us a stable basis, and we just discussed in our, question and answer session on the shortage of citriole and c citral derived products. We have a stated basis, and then we we're always convinced that this would work out. And you see this as a sign that we're making progress in the Pinnova acquisition. As, I recently said, we will until 2020 double the business, in T Mobile and T Mobile derived product. And this is clearly the sign that we deliver on our, on our, improvement, projects with the Pinova. So that is the strongest, a driver for growth, in the all my molecules. And and he set that up and said then then the ramp up costs will I want to say something? Yeah. So let me check it up. I I I capped the $2,000,000 out for our, Diana project in Georgia because it's a greenfield, project. It's in passing a huge project for the Diana Organization, and it will, need, to ramp up, the facility, including some personal costs that you will experience before it can start data this year. All the other projects are more in an ongoing environment. So we are expanding existing production facilities and that while we are not carving out the ramp up costs for these, investments explicitly, I think that is something that we have to bear as we go along. And should not be considered as one time effects. No. But you see some of these effects, in our numbers, just if I may add this for example, in mentorship, you're preparing for, the start of the production. So we're, we're, accumulating starting materials so that we have a safe supply. So some of these things are, visible if you go through our numbers. Mhmm. Okay. Thank you very much. The next question is from Craig King Price of Equinix. Please go ahead. A more general question on on the on the margin evolvement of some products. Put you put you, a lot of the limited houses, developing over the life cycle. So my my next assumption would be when you, have these, or you launching products that it's, at the beginning, there'd be no good address Bander Baff. I'm done, when it's maturing, again, below, group average. Is that, roughly okay or is it a little bit too simple? I would say this is almost simply fine. It will work for, to help you through this compositions in Flavors and fragrance. Yes. In the beginning, that ramp up costs and, marketing costs. And, typically a very good year if the product is successful the 2nd year, and everything went up and everything is done, marketing, introduction is done, and the product is in the early stages of the life cycle. So And I said, that is for flavors and fragrances. This does not apply to the ingredient factor, like nutrition, or like, aroma molecules or, like, cosmetic ingredients. Actually, there, if you have a great, well, good product, it becomes, typically more profitable going forward as most of the products which we are producing, for example, cosmetic ingredients are patent protected, which means you have a 20 year large span of of of harvesting, investment. On the downside is that typically in the investment up front in, particular and our monetary and cosmetic ingredients are more significant and you see that, for example, on our nutrition business where we're investing. So this is the other side. So please differentiate, the picture into compositions, flavor, and phrases, and ingredients. But for compositions to your picture, roughly would be correct. I hope that answers your question. Yes. Thank you very much. The next question is from Sing Tung. Ryan oferenberg. Please go ahead. Hello. Good morning, gentlemen. Two questions for me, please. Firstly, I wish you could elaborate further on free cash generation that we saw in the first half. And now you mentioned the CapEx spend for this year. As you look into 20 and the 2018 2019, it gives a sense of how do you think the working capital situation will evolve this year as well as this next year, particularly as a rough helping you capacity. And I wonder if you expect to further outflow as well as your coverage expectations. And secondly, in terms of the growth that was the 1st half, you give us a sense in terms of the growth rates between maybe the global customers and some of your more local regional customers In particular, are you seeing more difficulties in passing through the price increases in the global versus the smaller customers? Thank you. Okay. When you crash for a generation, Olaf, I think you picked that up and you take the numbers. I think there's some on on the global and regional it's a bit oversimplifying saying the business with the global or with the local customers grows faster than with the global ones. Actually, I'm happy to report our business where the global customer has developed also very nicely. Price increases I can tell you, since I'm always difficult, regardless if it's with global, regional, local customers, it depends on on on the customer basis. There's some at least momentum and the and the the necessities that price increases in this environment are necessary to speak with everyone regardless if it's a small or big customer, and they it's it's a question of a relationship you have with a customer. I would not say generally that it's it's more difficult with a global smart and with the with with the local customer. You have smart agents with one purchasing in all companies. So, we take it on a pragmatic basis. And, and, on the other side, the growth, also, the strong growth we showed showed come back from global customer. Or if you want to pick up this cash generation? Yes. So, as General already mentioned, the the CapEx ratio is expected to 6% this year. So that is the guidance for this part. For working capital, I think there are a few, drivers, of course, one is a very strong dose, and so that, connect It also leads to an increase in working capital. We have specific situations with the raw material price increases, which are also leads to a higher, valuation of, inventory at the end of the day. And as you have also, referred to that already. We are building some strategic inventory at the moment, to prepare for the launch of our new mental capacity. Most of you who are longer with us, from some time, first, might remember that we had shortages at that time. That should not happen again. And therefore, we are building this, downside as yet for temporary growth period. The inventory situation will be higher because of this. But I think it's Worldwide investment we are doing here to have a quick start early next year. Thank you. So it's fair to say that free cash generation of this year and next year. I'm trying to find a hopefully acceleration in the aggregators. Oh, yeah. Definitely. I mean, the the work heavily on the working capital side, to KPIs, there's a lot of attention in the organization. In the meantime, on the other hand, as I always said, this business model which we are running is capital intensive and it requires a certain amount of working capital network. So that doesn't mean that we are not sensitive around it. We are putting a lot of efforts into managing this, as tight as we can. Thank you very much. The next question is from Lee Korn of Davy. Please go ahead. Thank you. Good morning, gentlemen. Just two questions for me, please. So, firstly, on the emerging market growth, which was very strong in H1 12.8%. Do you really would you be able to split that between, the segments or between flavors and nutrition and symptom care? And then secondly, just to zone in on North America within flavor, you reported double digits organic sales growth. So just was there anything you particularly call out and then on that, what would be your view in terms of the medium term outlook for growth in North America. Thank you. So, miss, thanks for the question. The emerging markets growth, yes, is impressive, but it is a confirmation of what we said, sir. The opportunities, the growth in populations, and in our from a base was this and will continue to be in the emerging markets. On the other side, yes, we're aware, and we all have to be aware that is a challenging environment. The winners, today are the losers tomorrow in emerging markets. But if you're agile enough. And if you are, responsive enough, in the emerging markets, you typically find, nice areas and nice opportunities and the numbers which we just delivered and, showed, just confirmed that. And we do not see any reason why they should change, we also will continue to focus emerging markets. But as we said, we are aware that what the dry the growth today. It will probably be, having difficulties tomorrow, but that is, something which is typical for the emerging markets. North America and flavors saw a very strong growth indeed, but that shows, just a confirmation of our strategy building up that business. And we're we saw a strong growth all over. One area being vanilla, we have one being beverages, but there was not any weak area of flavors, which I would pick out. It is just the confirmation of, the initiatives which we have, have initiated in North America is being paid off. And looking forward, we have no reason to be, to be pessimistic in the future on that business. I hope that answers your questions. Okay. Thank you, sir. Yes. Thank you so much. Okay. Ladies and gentlemen, this concludes the end of our conference call. Thank you very much for your time and your interest in Sunrise. 9 months results will be published on November 7th. We are now looking forward to seeing you at coming conferences for roadshows. Goodbye and have a nice day. Alright. Ladies and gentlemen, the conference is now concluded. And you may disconnect your telephone. Thank you for joining and have a pleasant day. Goodbye.